The company manufactures a recombinant mammalian cell produced third-generation Sci-B-Vac in its biologics manufacturing facility in Rehovot, Israel.
The multiple clinical studies conducted on Sci-B-Vac have demonstrated that it produces sufficient antibodies in population of documented non and low-responders, for which conventional hepatitis B vaccines did not elicit adequate antibody production.
In addition, studies also show that the vaccine induces seroprotection and can be used for immunotherapy of chronic hepatitis B.
Opko acquired its stake in the Israeli company from FDS Pharma, which purchased the company in the first quarter of 2012, including Rehovot hepatitis vaccine manufacturing plant, vaccine production and marketing rights, from a Singapore biotechnology company, SciGen.
The financial terms of the deal have not been disclosed.